In the enlightened realm of phase 1 oncology trials there generally more unknown unknowns than there are known unknowns, especially with new target approaches.
Who knew it was so beautiful outside of the cold dark halls?!
You could say that makes for a more interesting world, but it also makes for more caution, especially when the FDA is considering agonists that induce stimulatory effects. What it means is that you start off very low – in this latest example it was 50µg and going up to 1600µg to determine the safety profile of a combination.
We have covered the STING pathway quite extensively over the last four or five years now, so it’s time for a new update and a look at some of the much awaited combination data. What can we learn?
To learn more and get a heads up on our latest oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
New Orleans – one of the presentations of note at Immunology 2015 (the annual meeting of the American Association of Immunologists) was by Thomas J. Gajewski MD, PhD from the University of Chicago. His presentation on “Innate immune sensing of cancer via the STING pathway” was well worth the trip to New Orleans.
Readers may recall the post we wrote in March on “What is STING and why does it matter in cancer immunotherapy?” It followed the news that Novartis were collaborating with Aduro Biotech (NASDAQ: ADRO) on agonists that activate the STING (Stimulator of Interferon Genes) signaling pathway in immune cells.
Dr Gajewski (pictured below) kindly spoke to BSB after his presentation at Immunology 2015.
Excerpts from the interview will feature on Episode 2 of the Novel Targets podcast (@TargetsPodcast). Subscribers can read more from the interview below.
You should read and/or buy access to this post if you don’t know the answers to the following:
- What role does the tumor microenvironment play in response to cancer immunotherapy?
- How could the tumor microenvironment be a biomarker of response to checkpoint inhibitors?
- Why target the STING pathway?
- Reasons Novartis are collaborating with Aduro Biotech?
- How may a STING agonist be brought to the clinic?
To learn more insights on this intriguing topic, subscribers can log-in or you can purchase access to BSB Premium Content.